Abstract
The purpose of this paper was to examine the effects of speech therapy and various pharmacological treatment approaches on the voice and speech of persons with Parkinsons disease (PD). Approximately 80% of PD patients have voice and speech problems including reduced vocal intensity, reduced vocal pitch, monopitch and monoloudness, and imprecise articulation. Research prior to 1970s had not demonstrated significant improvements following speech therapy. However, recent research has shown that speech therapy (when persons with PD are optimally medicated) has proven to be the most efficacious therapeutic method for improving voice and speech function. Across research studies, pharmacological methods of treatment in isolation do not appear to significantly improve voice and speech function in PD. In a single subject study, however, the dopamine agonist Mirapex was shown to have beneficial effects on vocal intensity. Possible explanations for the differential responses to treatment are discussed. It is suggested that the goal of future studies should be investigations of the effects of combined treatment approaches.
Keywords: parkinsons disease, speech therapy, mirapex, hypokinetic dysarthria
Current Medicinal Chemistry
Title: The Effects of Speech Therapy and Pharmacological Treatments on Voice and Speech in Parkinsons Disease: A Review of the Literature
Volume: 9 Issue: 14
Author(s): Geralyn M. Schulz
Affiliation:
Keywords: parkinsons disease, speech therapy, mirapex, hypokinetic dysarthria
Abstract: The purpose of this paper was to examine the effects of speech therapy and various pharmacological treatment approaches on the voice and speech of persons with Parkinsons disease (PD). Approximately 80% of PD patients have voice and speech problems including reduced vocal intensity, reduced vocal pitch, monopitch and monoloudness, and imprecise articulation. Research prior to 1970s had not demonstrated significant improvements following speech therapy. However, recent research has shown that speech therapy (when persons with PD are optimally medicated) has proven to be the most efficacious therapeutic method for improving voice and speech function. Across research studies, pharmacological methods of treatment in isolation do not appear to significantly improve voice and speech function in PD. In a single subject study, however, the dopamine agonist Mirapex was shown to have beneficial effects on vocal intensity. Possible explanations for the differential responses to treatment are discussed. It is suggested that the goal of future studies should be investigations of the effects of combined treatment approaches.
Export Options
About this article
Cite this article as:
Schulz M. Geralyn, The Effects of Speech Therapy and Pharmacological Treatments on Voice and Speech in Parkinsons Disease: A Review of the Literature, Current Medicinal Chemistry 2002; 9 (14) . https://dx.doi.org/10.2174/0929867023369808
DOI https://dx.doi.org/10.2174/0929867023369808 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design Editorial [ Hot Topic : Receptor Dimerization and Bivalent Ligands, an Emerging Topic for Drug Design (Guest Editor: Dr. Ao Zhang) ]
Current Topics in Medicinal Chemistry In Silico ADME and QSAR Studies on a Set of Coumarin Derivatives As Acetylcholinesterase Inhibitors Against Alzheimer’s Disease: CoMFA, CoMSIA, Topomer CoMFA, and HQSAR
Letters in Drug Design & Discovery Perceptions in Type 1 Diabetes Mellitus with or Without the Use of Insulin Pump: An Online Study
Current Diabetes Reviews Autophagy to the Rescue
Current Neurovascular Research 3D-QSAR and in-silico Studies of Natural Products and Related Derivatives as Monoamine Oxidase Inhibitors
Current Neuropharmacology Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Exploration of N-arylpiperazine Binding Sites of D2 Dopaminergic Receptor
Mini-Reviews in Medicinal Chemistry Progranulin Mutations in Ubiquitin-Positive Frontotemporal Dementia Linked to Chromosome 17q21
Current Alzheimer Research Functional and Structural MRI Biomarkers to Detect Pre-Clinical Neurodegeneration
Current Alzheimer Research Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Different Inductive Effects of Praziquantel Racemate and its Enantiomers on the Enzyme CYP3A4 Mediated by Pregnane X Receptor and its Variants
Current Drug Metabolism Do Human Lipoxygenases have a PDZ Regulatory Domain?
Current Molecular Medicine Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein
Mini-Reviews in Medicinal Chemistry Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Relevance of Mutations in Tau for Understanding the Tauopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Efficacy of HGF Gene Transfer for Various Nervous Injuries and Disorders
Central Nervous System Agents in Medicinal Chemistry 6-hydroxydopamine Lesion of the Mesolimbic Dopamine System Alters Morphine-Induced Conditioned Reinforcement
Current Psychopharmacology